Skip to main content

Table 3 Correlations and associations between the MBDA score and radiographic progression or bone turnover markers

From: The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies

Measure Time point or period for comparison with MBDA score Number of available samples r p value β (95% CI)1 p value
∆SHS (baseline-12 months)2 BL 11 0.19 0.57 0.34 (−0.33–1.01) 0.23
6 M 11 0.18 0.60 0.18 (−0.72–1.08) 0.62
11 0.19 0.57 −0.38 (−1.35–0.60) 0.34
Bone turnover markers3
 βCTX 23 0.22 0.31 1.10 (−6.79–8.99) 0.77
 P1NP 23 −0.14 0.54 −0.31 (−2.05–1.42) 0.70
 BAP 23 −0.01 0.98 −0.01 (− 0.17–0.15) 0.88
 TRAP5b 23 −0.20 0.37 0.00 (−0.03–0.03) 0.99
 DKK1 23 0.27 0.22 0.15 (−0.40–0.69) 0.57
 Sclerostin 23 0.11 0.63 0.10 (−0.37–0.56) 0.66
  1. SHS Sharp/van der Heijde score, βCTX beta-isomerised carboxy terminal telopeptide of type I collagen, P1NP procollagen type 1 amino-terminal propeptide, TRAP5b tartrate-resistant acid phosphatase isoenzyme 5b, DKK1 Dickkopf-1, BAP bone-specific alkaline phosphatase, MBDA multi-biomarker disease activity, BL MBDA score at baseline, 6 M MBDA score at month 6, ∆ change (for SHS: ∆MBDA score from baseline to month 6 and ∆SHS from baseline to month 12; for bone turnover markers: both ∆ from baseline to month 6), r Spearman’s rank correlation, CI confidence interval
  2. 1β: regression coefficient from multivariable linear regression analysis, after adjustment by age, gender and/or menopausal status, smoking status, RF status, and ACPA status
  3. 2UMC Utrecht cohort only
  4. 3HORUS cohort only